Standard antiemetic treatment
Phase 3Small molecule
Standard antiemetic treatment is one of 56 small molecule programs targeting Chemotherapy-induced nausea and vomiting. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Tykerb
GSKPreclinical
Prolia
AmgenPreclinical
Standard antiemetic treatment
JJiuda Zhao
Phase 3
Cymbalta
Alnylam PharmaceuticalsPreclinical
Zolymbus
AbbViePreclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Acupan
YYonsei University
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chemotherapy-induced nausea and vomiting1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- JJiuda Zhao